Skip to main content

Table 2 Summary of antipurinergic therapy results in the Fragile X mouse model of autism spectrum disorders

From: Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Feature Abnormality in Fragile X males vs. FVB controls Response to antipurinergic therapy
Social preference Decreased Normalized (P <0.05)
Social novelty Decreased Normalized (P <0.05)
T-maze spontaneous alternation Decreased Normalized (P <0.001)
Marble burying Decreased Normalized (P <0.05)
Core body temperature Decreased Normalized (P <0.001)
Acoustic startle Decreased [sic] Unchanged (P = ns)
Metabolomics (60 pathways measured) 20 of 60 pathways disturbed 33 metabolites increased and 25 decreased of 58 changed
Synaptosomal structure by electron microscopy Fragile and malformed post-synaptic densities; Accumulation of electron dense matrix material Improved
Synaptosomal proteins (54 interrogated) N/A 17 proteins were changed (for example, decreased PI3/GSK3β, GluR1, C1q, and APP; increased PPARβ/δ)
Locomotor activity - total distance (hyperactivity), center exploration, holepokes, rearing None N/A